DNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ginkgo Bioworks Holdings Inc (DNA) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock has shown significant price decline recently, lacks positive trading signals, and has weak financial performance. While there are no strong positive catalysts, the negative catalysts and lack of clear growth visibility make this stock a hold rather than a buy.
The technical indicators show a neutral trend. The MACD histogram is positive but contracting, RSI is neutral at 37.227, and moving averages are converging. Key support is at 6.422, and resistance is at 7.446. The stock is trading close to its support level, but there is no strong indication of a reversal or upward momentum.
No significant positive catalysts identified. The company has no recent news or events indicating a positive shift.
The stock has experienced a significant regular market price drop of -12.91%. Analysts have lowered price targets, and the company divested its biosecurity business, limiting guidance to cash burn. Financial performance shows a sharp revenue decline (-56.39% YoY) and negative net income, despite some improvement in EPS.
In Q3 2025, revenue dropped significantly by -56.39% YoY to $38.84 million. Net income improved but remains negative at -$80.76 million, and EPS increased to -1.45. Gross margin declined to 67.04%, down -22.52% YoY, reflecting operational challenges.
Mixed to negative. BTIG maintains a Sell rating with a lowered price target of $5, citing limited growth visibility. TD Cowen maintains a Buy rating but lowered its price target to $12, emphasizing the need for clear multi-year growth frameworks.
